Jason V Evans, Shankar Suman, Mounika Uttam L Goruganthu, Elena E Tchekneva, Shuxiao Guan, Rajeswara Rao Arasada, Anneliese Antonucci, Longzhu Piao, Irina Ilgisonis, Andrey A Bobko, Benoit Driesschaert, Roman V Uzhachenko, Rebecca Hoyd, Alexandre Samouilov, Joseph Amann, Ruohan Wu, Lai Wei, Aaditya Pallerla, Sergey V Ryzhov, Igor Feoktistov, Kyungho P Park, Takefumi Kikuchi, Julio Castro, Alla V Ivanova, Thanigaivelan Kanagasabai, Dwight H Owen, Daniel J Spakowicz, Jay L Zweier, David P Carbone, Sergey V Novitskiy, Valery V Khramtsov, Anil Shanker, Mikhail M Dikov
BACKGROUND: We investigated the role of A2B-adenosine receptor (A2BAR) in regulating immunosuppressive metabolic stress in the tumor microenvironment (TME). Novel A2BAR antagonist PBF-1129 was tested for anti-tumor activity in animals and evaluated for safety and immunological efficacy in a phase-I clinical trial in non-small-cell lung cancer (NSCLC) patients. METHODS: Anti-tumor efficacy of A2BAR antagonists and impact on metabolic and immune TME was evaluated in lung, melanoma, colon, breast and EGFR-inducible transgenic cancer models...
May 17, 2023: Journal of the National Cancer Institute